Scientists Rewire Donor Stem Cells To Outsmart Aggressive Blood Cancers

Researchers reported early trial results for a CRISPR-edited donor stem cell transplant approach in AML and MDS.

The donor cells were engineered to remove CD33, aiming to protect healthy blood cells during later CD33-targeted therapy.

Early outcomes looked similar to standard transplant results, suggesting the method may be feasible and safe enough to advance.

If confirmed, the strategy could make follow-up immunotherapies like CAR-T or other CD33-targeted treatments more effective and less toxic.